DUBLIN , Aug. 3, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced the publication of a new manuscript examining whether baseline penile pain influences treatment outcomes in men with Peyronie's...
DUBLIN , July 30, 2026 /PRNewswire/ -- Keenova Therapeutics plc , a leading developer and manufacturer of branded therapeutics, announced today that it will report its second quarter 2026 financial...
DUBLIN , July 13, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced the publication of a new manuscript about the use of Acthar Gel (repository corticotropin injection) to treat certain severe...
DUBLIN , July 8, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today positive results from its Phase 3 clinical trial of XIAFLEX ® (collagenase clostridium histolyticum) for the treatment...
Reddit AMA and New Sexual Health Screening Tool Headline the Awareness Month
DUBLIN , May 15, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that new and final updated data from its dedicated ventral curvature analysis of Peyronie's disease and XIAFLEX ®...
Strong First-Quarter Performance Driven by Acthar ® Gel 1 and XIAFLEX ® 2
Dupuytren's contracture, a.k.a. Viking Hand, is a progressive hand condition affecting an estimated 13 million Americans
DUBLIN , May 1, 2026 /PRNewswire/ -- Keenova Therapeutics plc announced today that a new presentation on hepatorenal syndrome-acute kidney injury (HRS‑AKI) and TERLIVAZ ® (terlipressin) will...
DUBLIN , April 30, 2026 /PRNewswire/ -- Keenova Therapeutics plc , a leading developer and manufacturer of branded therapeutics, announced today that it will report its first quarter 2026 financial...